NASDAQ
Nanobiotix S.A. - ADSs (NBTX)
♥ 562 Thanks from members
Nanobiotix S.A. exhibits mixed-to-bullish sentiment driven by its physics-based oncology approach, a successful upsized $100 million global follow-on offering in May 2026, and recognition among small-cap hedge fund favorites despite being viewed as a highly speculative clinical-stage bet.